The integrase strand transfer inhibitors (INSTIs) are the newest antiretroviral class in the HIV treatment armamentarium. Dolutegravir (DTG) is the only second-generation INSTI with FDA approval (2013). It has potential advantages in comparison to first-generation INSTI's, including unboosted daily dosing, limited cross resistance with raltegravir and elvitegravir, and a high barrier to resistance. Clinical trials have evaluated DTG as a 50-mg daily dose in both treatment-naïve and treatment-experienced, potency against single mutations from any of the three major INSTI pathways ( Y143, H155, Q148) ; however, the Q148 mutation with two or more additional mutations significantly reduced its potency. The long-acting formulation of DTG, GSK1265744LA, is the next innovation in this second-generation INSTI class, holding promise for the future of HIV prevention and treatment.
INSTI-naïve participants. In those treatmentnaïve participants with baseline viral load \100,000 copies/mL, DTG combined with abacavir and lamivudine was non-inferior and superior to fixed-dose combination emtricitabine/tenofovir/efavirenz. DTG was also superior to the protease inhibitor regimen darunavir/ritonavir in treatment-naïve participants regardless of baseline viral load. Table 1 ). The INSTI mechanism of action is to prevent HIV integrase from incorporating proviral DNA into the human host cell, thus inhibiting the HIV-catalyzed strand transfer step. This step has no human homolog, making it a specific and effective HIV drug target with excellent tolerability and minimal toxicity.
The INSTI's are generally metabolized by glucuronidation by the hepatic enzyme UGT1A1. EVG is unique among this drug class as it is primarily metabolized by the potent hepatic and intestinal cytochrome P450 (CYP3A4); for this reason, EVG must be pharmacokinetically boosted with a CYP3A4
inhibitor. Cobicistat (COBI) is currently FDA approved for this purpose in a combination ''quad'' pill: EVG/COBI/tenofovir (TDF)/ emtricitabine (FTC).
INSTI: THE FIRST GENERATION
Numerous clinical trials have investigated optimal dosing and efficacy of the integrase inhibitors. RAL 800 mg daily dosing is statistically inferior (P = 0.04) to 400-mg [3] , and sustained to 156 weeks [4] . The RAL regimen has fewer adverse events and significantly less elevation of fasting lipids from baseline to week 144 when compared to EFV [4] . The maker of RAL, Merck, funded these studies.
The daily fixed-dose combination EVG/ COBI/TDF/FTC is also non-inferior to FTC/ TDF/EFV at 48 weeks [5] , 96 weeks [6] and sustained to 144 weeks [7] . When tested against the combination FTC/TDF plus a daily protease inhibitor backbone regimen atazanavir 300 mg/ritonavir 100 mg (ATZ/r), EVG/COBI/ TDF/FTC is non-inferior at 48 weeks [8] and 96 weeks [9] . These studies support the durable efficacy and safety profile of this INSTI daily formulation. Gilead, the maker of EVG and the ''quad'' pill, funded these studies.
Based on these clinical trials data, RAL in combination with FTC/TDF is a recommended first-line therapy for starting ART [10] [11] [12] . EVG in the form of the ''quad'' pill is also an acceptable starting regimen for ART-naïve patients with pre-treatment creatinine clearance [70 mL/min [10] . Monitoring creatinine is necessary as COBI blocks the renal tubular secretion, though with no appreciable affect on glomerular filtration rate (GFR).
INSTI: THE NEXT GENERATION
Dolutegravir is the latest ART agent to be FDA approved. It is a second-generation integrase Understanding the correlation of doseresponse and change in HIV-1 RNA informs optimal dosing, especially if higher doses carry safety concerns. The PD of DTG was evaluated in a phase 2a placebo-controlled trial among HIV-infected, INSTI-naïve participants. DTG 2, 10, or 50 mg versus placebo were randomly assigned, and the plasma drug level and rate of HIV RNA decline were measured [16] . The PA-IC 90 was maintained with daily dosing of 50 mg DTG throughout a 10-day dosing interval with a well-described exposure-response relationship, low inter-patient variability, and predictable PK-PD properties [16] . Potency was demonstrated with a 2.5 log 10 copies/mL mean decline in viral load after receiving 10 consecutive days of 50 mg daily DTG as monotherapy; 70% (7/10) had viral load \50 copies/mL by day 10 of monotherapy which was sustained to day 14 [16] .
Given these promising data, PK studies evaluated DTG for interactions with potential ART combinations. ATZ is a PI that is a UGT1A1 inhibitor. Concurrent dosing of ATZ 300 mg daily or ATZ/r (300/100 mg, respectively) with DTG was found to be safe, not requiring dose adjustment when combined with DTG [17] . Similar studies evaluated the combination of etravirine (200 mg twice daily), a NNRTI and a CYP34A inducer, as well as etravirine plus the PI combination lopinavir/ritonavir (200/400/ 100 mg twice daily, respectively). Though the CYP34A metabolic pathway of DTG is minor, etravirine did significantly reduce the exposure of DTG such that this combination without a boosted PI should be avoided [18] . When coadministered with a PI, however, the inhibitory effect of UGT1A1 presumably counteracts the inducement of CYP34A and no dose adjustment is necessary with this triple ART regimen [18] .
RESISTANCE
Genotypic assays identify specific mutations that may be associated with phenotypic resistance. DTG was specifically engineered to deliver a novel resistance profile to avoid cross resistance with the first-generation INSTI class and to maintain a high barrier to resistance [19] . an off-rate 5-40 times slower than RAL and EVG (P\0.0001) ( Fig. 1) [20] . This slow dissociation may contribute to DTG's high barrier to resistance and suggests that prolonged binding plays a role in its unique resistance profile [20, 21] . Single mutations of the major RAL pathway Y143, N155, and Q148 do not increase DTG- [26] . In a non-inferiority trial, clinical equivalence should be clearly defined such that non-inferiority is demonstrated when the 95% confidence interval (CI) falls entirely to the right of the lower limit (-D). If the 95% CI of the tested treatment effect lies both above the lower limit of the pre-specified difference (-D) and above zero, the trial was properly designed and carried out in accordance with requirements of a non-inferiority trial, and the two-sided P value for superiority is presented according to the intention to treat (ITT) principle remains significant (P\0.05), then superiority may also be claimed [26] .
TRIALS AMONG ART-NAÏVE PARTICIPANTS
SPRING-1 (NCT00951015) is a dose-finding study comparing the increasing daily doses of DTG 10, 25, or 50 mg to efavirenz 600 mg with a dual-NRTI background regimen (FTC/TDF or abacavir (ABC)/lamivudine (3TC) in a randomized, open-label (dose-masked) trial [27] . Participants and investigators were not blinded to the study drug, but were blind to the DTG dose. Across the dosing spectrum of DTG, the rate of viral decay was robust and 50 mg daily dosing of DTG remained efficacious and well tolerated to 48 and 96 weeks [27, 28] . No treatment-emergent mutations were detected [28] . Creatinine clearance rose in week 1, gradually returning to baseline by week 48. Lipid profile was more favorable than with EFV with little to no increase from baseline [27, 28] . SPRING-2 (NCT01227824) followed as the first trial to compare the efficacy of two INSTI's head to head: 400-mg twice-daily RAL versus 50-mg once-daily DTG in ART-naïve patients [29] . DTG was found to be non-inferior to RAL at 48 weeks, regardless of NRTI background regimen, with 88% versus 85% participants with HIV-1 RNA \50 copies/mL. Noninferiority was sustained to 96 weeks (81% versus 76%, respectively) [30] . Fewer participants in the DTG group had protocoldefined virologic failure (8 versus 18), and no treatment-emergent resistance mutations were noted in the DTG arm. Of note, virologic failure was conservatively defined as two consecutive viral load measures [50 copies/mL. If participants were followed to a higher viral load, perhaps increased levels of resistance would have been detected; therefore lack of emergent resistance should be interpreted with caution [31] . Though safety in both arms was excellent, an increase in alanine aminotransferase (ALT) with possible druginduced liver injury (DILI) was noted, one case in each study arm. SINGLE (NCT01263015) is a randomized, double-blinded trial, comparing DTG plus ABC/3TC to the fixed-dose combination FTC/ TDF/EFV in a non-inferiority statistical design [32] . The DTG arm had a rapid viral decay, with 28 days to viral suppression (\50 copies/mL) versus 84 days in the EFV arm (P\0.0001). In the DTG arm, 88% had HIV-1 RNA \50 copies/ mL at 48 weeks compared to 81% receiving EFV. This result met non-inferiority criteria, and also superiority (P = 0.003) in the ITT analysis with the 95% CI not crossing zero. The superior responses were primarily driven by less discontinuation of the DTG ? ABC/3TC
regimen as compared to FTC/TDF/EFV due to adverse events, (primarily neuropsychiatric with EFV and insomnia with DTG) (Fig. 2) . When stratified by baseline viral load, those with HIV RNA [100,000 copies/mL (*25%)
revealed an even greater distinction with 93% of those in the DTG arm suppressed versus 70% in the DRV/r arm. Fewer adverse events and withdrawals occurred in the DTG group, and likely contributed to statistical superiority [34] ( Fig. 2) .
CLINICAL TRIALS OF DOLUTEGRAVIR IN TREATMENT OF ART-EXPERIENCED PATIENTS
In SAILING (NCT01231516), ART-experienced, INSTI-naïve participants were randomized (1:1) to 50-mg daily DTG or 400-mg twice-daily RAL plus investigator-selected background therapy.
SAILING was the first and thus far only DTG study to include resource-limited settings. VIKING (NCT00950859) was the first study to evaluate DTG activity among participants with genotypic RAL resistance in a standard 50-mg daily dose (Cohort 1) [22] . During this study, a protocol amendment to include a cohort receiving twice-daily 50-mg DTG was created to compare efficacy (VIKING Cohort 2).
Twice-daily dosing was found to be more efficacious both at day 10 (96% versus 78% for the primary endpoint of C0.7 log 10 copies/mL change from baseline in HIV-1 RNA or \400 copies/mL) and at week 24 after optimizing the background regimen (OBR) (75% versus 41% with HIV-1 RNA \50 copies/mL). Those with viral mutations including Q148H/K/R plus G140S plus additional RAL mutations had a reduced response to DTG.
VIKING-3
(NCT01328041) further investigated the use of DTG in treating INSTIexperienced participants failing their current regimen (viral load [500 copies/mL). DTG was substituted for the first-generation INSTI, acting essentially as functional monotherapy until day 8 when OBR occurred [23] . On day 8 of DTG 50 mg twice daily, the average change of HIV-1 RNA from baseline was -1.43 log 10 copies/mL (95% CI -1.52, -1.34). DTG was continued with OBR with at least one active drug on day 8, with 69% achieving \50 copies/mL at week 24, and 63% at week 48 [36] . The presence of Q148 plus C2 additional mutations was associated with reduced viral decay as compared to those with no Q148 mutation at baseline (P\0.001). Baseline INSTI resistance (genotypic and phenotypic) and baseline viral load were highly significant predictors of response at week 24. For every twofold increase in DTG change, the odds of virologic suppression to \50 copies/mL were 63% lower, and were 96% lower if the virus contained Q148 ?C2 mutations. VIKING 4 (unpublished; NCT01568892) is designed similar to VIKING 3, but with a randomized (1:1), double-blind placebo study design to quantitatively evaluate antiviral activity specifically attributed to DTG [37] .
Results of this study are not yet published.
PEDIATRIC FORMULATIONS
IMPAACT study P1093 (NCT01302847) is an ongoing Phase I/II safety and dose-finding study for treatment-experienced, INSTI-naïve infants, children and adolescents. Similar to the VIKING studies, DTG is first added to a failing regimen for 5-10 days, then OBR for further follow-up.
This study is composed of five age-related cohorts ranging from [6 weeks up to 18 years. Data for the oldest two cohorts have been presented at scientific meetings [38] [39] [40] . The first cohort [12 and \18 years provided data contributing to the FDA label approving DTG down to 12 years of age with a weight minimum of 40 kg [24] . These pediatric studies measure virologic suppression \400 copies/mL at 24 weeks (83%) [38] and 48 weeks (74%) with an additional secondary endpoint as \50 copies/mL (70% and 61%, respectively) [39] . Virologic failure (\400 copies/mL) at week 48 in all 6 of 23 adolescents was attributed to incomplete adherence based on a 3-day pill recall questionnaire. There were no DTG drug-related adverse events and no discontinuations. The target area under the curve at 24 h (AUC 24 ) and concentration at 24 h (C 24 ) were achieved with *1 mg/kg dosing [39, 40] . A pediatric granule formulation has been developed and tested, demonstrating that drug exposure exceeds that of the tablet form, is palatable, and can be given without food or liquid restrictions [41] .
ADVERSE EVENTS AND SIDE EFFECTS
Creatinine typically rises in the first 2 weeks after starting DTG, returning to baseline by 48 weeks [27, 29] . This rise in creatinine is attributed to DTG's potent inhibition of human organic cation transporter (OCT2) that inhibits proximal renal tubular creatinine secretion without affecting GFR, similar to other drugs including trimethoprim and cimetidine [42] . 
LONG-ACTING AGENT GSK1265744LA
GSK1265744, a distinct integrase inhibitor from the same chemical series as DTG, can be formulated as a crystalline nanoparticle suspension and is thereby amenable to delivery as a long-acting injectable (744LA).
The 744LA formulation has unique properties including high potency (PA-IC 90 166 ng/mL), poor water solubility (\10 lg/mL), slow metabolism, and high melting point, allowing it to be formulated as a nanoparticle solution [49, 50] . The t 1/2 ranges from 21 to 50 days.
Phase I studies demonstrate that this compound is safe and well tolerated with plasma concentrations above the PA-IC 90 for 24 weeks or longer with doses 200 mg or greater [51] .
The 744LA formulation in combination with the long-acting rilpivirine formulation (TMC278 LA) is being developed for use in treatment of HIV-infected patients. This combination holds potential promise to expand HIV treatment options by providing an innovative mechanism to improve adherence, eliminate NRTI-and/or ritonavirrelated drug toxicities, and potentially enhance drug delivery to reservoirs such as lymphoid tissue and the central nervous system based on preliminary data of a macrophage-carriage system for nanoformulated crystalline ART in experimental animal models [49, 52, 53] .
The 744LA formulation is also being developed as a single agent for pre-exposure prophylaxis (PrEP as compared with rectal tissue [54] . The amount of drug penetration into genital tract tissues and fluids needed to prevent infection is unknown. 
SUMMARY

